Ajit Motwani

On the overall revenue guidance for FY25, we have been given guidance of 15%- 20%. Our Q1 numbers are at about 8%. Would you be able to throw some light on the sense that it is under review, or you are still confident of delivering on those growth numbers?

On the CSM business, I think this quarter was 13% . That business, since you have some visibility because of the order book, on that business, do you see delivering on those heightened numbers?

And one last question on the pharma business . From the time we acquired, the revenues have come off very sharply. I know you alluded issues in two products, but apart from that, the discussion or the deferral of the client, can you just elaborate to us, is it beyond products?